The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody ...

Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, has received conditional approval from the European ...

Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab) has been granted conditional marketing approval by the European Commission (EC) to treat relapsed and refractory (R/R) multiple myeloma (MM).

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to ...

The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic (linvoseltamab) for adults with relapsed and refractory (R/R ...